Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
- Tuesday, November 2, 2021, 6:07
- Finance
- Add a comment
CARLSBAD, Calif., Nov. 2, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly known as IONIS-APOCIII-LRx. The CORE study is evaluating…
About the Author
adminasapcorp has written 39059 stories on this site.